These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Sfikakis PP; Charalambopoulos D; Vayiopoulos G; Oglesby R; Sfikakis P; Tsokos GC Clin Exp Rheumatol; 1994; 12(1):5-9. PubMed ID: 7909280 [TBL] [Abstract][Full Text] [Related]
3. Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Kiener H; Graninger W; Machold K; Aringer M; Graninger WB Clin Exp Rheumatol; 1994; 12(5):483-7. PubMed ID: 7842528 [TBL] [Abstract][Full Text] [Related]
4. Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. Søndergaard K; Stengaard-Pedersen K; Zachariae H; Heickendorff L; Deleuran M; Deleuran B Br J Rheumatol; 1998 Mar; 37(3):304-10. PubMed ID: 9566672 [TBL] [Abstract][Full Text] [Related]
5. Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations. Thakkar V; Patterson KA; Stevens W; Wilson M; Roddy J; Sahhar J; Proudman S; Hissaria P; Nikpour M Clin Rheumatol; 2018 Jun; 37(6):1563-1571. PubMed ID: 29687288 [TBL] [Abstract][Full Text] [Related]
6. Implication of intercellular adhesion molecule-1 (ICAM-1) and serum N(G)-hydroxy-L-arginine (L-NHA) in the pathogenesis of systemic sclerosis. Zamzam ML; Yassin MM; Sallam MM Egypt J Immunol; 2003; 10(2):27-38. PubMed ID: 15719609 [TBL] [Abstract][Full Text] [Related]
7. Expression of intercellular adhesion molecule-1 (ICAM-1) in the skin of patients with systemic scleroderma. Majewski S; Hunzelmann N; Johnson JP; Jung C; Mauch C; Ziegler-Heitbrock HW; Riethmüller G; Krieg T J Invest Dermatol; 1991 Oct; 97(4):667-71. PubMed ID: 1682392 [TBL] [Abstract][Full Text] [Related]
8. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Gruschwitz MS; Hornstein OP; von Den Driesch P Arthritis Rheum; 1995 Feb; 38(2):184-9. PubMed ID: 7848308 [TBL] [Abstract][Full Text] [Related]
9. Serum levels of soluble TNF alpha receptor type I and the severity of systemic sclerosis. Majewski S; Wojas-Pelc A; Malejczyk M; Szymanska E; Jablonska S Acta Derm Venereol; 1999 May; 79(3):207-10. PubMed ID: 10384918 [TBL] [Abstract][Full Text] [Related]
10. Increased frequency of in vivo hprt gene-mutated T cells in the peripheral blood of patients with systemic sclerosis. Sfikakis PP; Tesar J; Theocharis S; Klipple GL; Tsokos GC Ann Rheum Dis; 1994 Feb; 53(2):122-7. PubMed ID: 8129457 [TBL] [Abstract][Full Text] [Related]
11. Increased circulating soluble vascular adhesion protein-1 levels in systemic sclerosis: association with lower frequency and severity of interstitial lung disease. Yanaba K; Yoshizaki A; Muroi E; Ogawa F; Shimizu K; Sato S Int J Rheum Dis; 2013 Aug; 16(4):442-7. PubMed ID: 23992266 [TBL] [Abstract][Full Text] [Related]
12. Bioactivity of prolactin in systemic sclerosis. La Montagna G; Meli R; Criscuolo T; D'Angelo S; Valentini G Clin Exp Rheumatol; 2004; 22(2):145-50. PubMed ID: 15083880 [TBL] [Abstract][Full Text] [Related]
13. Circulating intercellular adhesion molecule 1 as a new activity marker in patients with systemic lupus erythematosus. Kling E; Bieg S; Boehme M; Scherbaum WA Clin Investig; 1993 Apr; 71(4):299-304. PubMed ID: 8097124 [TBL] [Abstract][Full Text] [Related]
14. Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma. Ihn H; Fujimoto M; Sato S; Kikuchi K; Igarashi A; Soma Y; Takehara K J Am Acad Dermatol; 1994 Oct; 31(4):591-5. PubMed ID: 7916356 [TBL] [Abstract][Full Text] [Related]
15. Expression and shedding of intercellular adhesion molecule 1 and lymphocyte function-associated antigen 3 by normal and scleroderma fibroblasts. Effects of interferon-gamma, tumor necrosis factor alpha, and estrogen. Shi-Wen X; Panesar M; Vancheeswaran R; Mason J; Haskard D; Black C; Olsen I; Abraham D Arthritis Rheum; 1994 Nov; 37(11):1689-97. PubMed ID: 7526872 [TBL] [Abstract][Full Text] [Related]
16. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis. Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328 [TBL] [Abstract][Full Text] [Related]
17. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Andersen GN; Caidahl K; Kazzam E; Petersson AS; Waldenström A; Mincheva-Nilsson L; Rantapää-Dahlqvist S Arthritis Rheum; 2000 May; 43(5):1085-93. PubMed ID: 10817563 [TBL] [Abstract][Full Text] [Related]
18. Elevated expression of beta 1 and beta 2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Sollberg S; Peltonen J; Uitto J; Jimenez SA Arthritis Rheum; 1992 Mar; 35(3):290-8. PubMed ID: 1371389 [TBL] [Abstract][Full Text] [Related]
19. Serum levels of vascular dysfunction markers reflect disease severity and stage in systemic sclerosis patients. Cossu M; Andracco R; Santaniello A; Marchini M; Severino A; Caronni M; Radstake T; Beretta L Rheumatology (Oxford); 2016 Jun; 55(6):1112-6. PubMed ID: 26989111 [TBL] [Abstract][Full Text] [Related]
20. Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts. Raschi E; Chighizola CB; Cesana L; Privitera D; Ingegnoli F; Mastaglio C; Meroni PL; Borghi MO Arthritis Res Ther; 2018 Aug; 20(1):187. PubMed ID: 30157947 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]